RU2008140661A - APPLICATION OF ANTIBODY FOR TREATMENT OF AUTOIMMUNE DISEASES IN A PATIENT WITH AN INadequate RESPONSE TO TNF-ALPH INHIBITOR - Google Patents

APPLICATION OF ANTIBODY FOR TREATMENT OF AUTOIMMUNE DISEASES IN A PATIENT WITH AN INadequate RESPONSE TO TNF-ALPH INHIBITOR Download PDF

Info

Publication number
RU2008140661A
RU2008140661A RU2008140661/14A RU2008140661A RU2008140661A RU 2008140661 A RU2008140661 A RU 2008140661A RU 2008140661/14 A RU2008140661/14 A RU 2008140661/14A RU 2008140661 A RU2008140661 A RU 2008140661A RU 2008140661 A RU2008140661 A RU 2008140661A
Authority
RU
Russia
Prior art keywords
mammal
antibody
use according
week
response
Prior art date
Application number
RU2008140661/14A
Other languages
Russian (ru)
Other versions
RU2489166C2 (en
Inventor
Марк БЕНЬЮНЕС (US)
Марк БЕНЬЮНЕС
Original Assignee
Джинентех, Инк. (US)
Джинентех, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джинентех, Инк. (US), Джинентех, Инк. filed Critical Джинентех, Инк. (US)
Publication of RU2008140661A publication Critical patent/RU2008140661A/en
Application granted granted Critical
Publication of RU2489166C2 publication Critical patent/RU2489166C2/en

Links

Abstract

1. Применение антитела, которое связывается с CD20, для производства лекарственного средства для лечения ревматоидного артрита у млекопитающего с неадекватным ответом на ингибитор TNFα, при котором млекопитающее имеет ACR50 ответ на 24-й неделе, ACR70 ответ на 24-й неделе или не имеет прогрессивного развития эрозий на 24-й неделе и далее. ! 2. Применение по п.1, в котором млекопитающим является человек. ! 3. Применение по п.1, в котором антитело не конъюгировано с цитотоксическим агентом. ! 4. Применение по п.1, в котором антителом является ритуксимаб. ! 5. Применение по п.1, в котором антитело является гумманизированным антителом 2Н7 v16, содержащим вариабельные домены, представленные SEQ ID Nos. 1 и 2. ! 6. Применение по п.1, при котором лекарственное средство применяется для лечения млекопитающего в способе, который, по существу, заключается во введении млекопитающему антагониста. ! 7. Применение по п.1, при котором антитело вводится в качестве двух внутривенных доз по 1000 мг. ! 8. Применение по п.1, при котором млекопитающее дополнительно получают сопутствующую терапию метотрексатом (МТХ). ! 9. Применение по п.8, при котором млекопитающее дополнительно лечат кортикостероидами. ! 10. Применение по п.9, при котором кортикостероиды включают метилпреднизолон и преднизолон. 1. The use of an antibody that binds to CD20 for the manufacture of a medicament for the treatment of rheumatoid arthritis in a mammal with an inadequate response to a TNFα inhibitor in which the mammal has an ACR50 response at week 24, an ACR70 response at week 24, or is not progressive the development of erosion in the 24th week and beyond. ! 2. The use according to claim 1, in which the mammal is a human. ! 3. The use according to claim 1, in which the antibody is not conjugated to a cytotoxic agent. ! 4. The use according to claim 1, in which the antibody is rituximab. ! 5. The use according to claim 1, in which the antibody is a humanized antibody 2H7 v16 containing the variable domains represented by SEQ ID Nos. 1 and 2.! 6. The use according to claim 1, wherein the drug is used to treat a mammal in a method which essentially consists in administering an antagonist to the mammal. ! 7. The use according to claim 1, wherein the antibody is administered as two intravenous doses of 1000 mg. ! 8. The use according to claim 1, in which the mammal additionally receive concomitant therapy with methotrexate (MTX). ! 9. The use of claim 8, wherein the mammal is further treated with corticosteroids. ! 10. The use of claim 9, wherein the corticosteroids include methylprednisolone and prednisolone.

Claims (10)

1. Применение антитела, которое связывается с CD20, для производства лекарственного средства для лечения ревматоидного артрита у млекопитающего с неадекватным ответом на ингибитор TNFα, при котором млекопитающее имеет ACR50 ответ на 24-й неделе, ACR70 ответ на 24-й неделе или не имеет прогрессивного развития эрозий на 24-й неделе и далее.1. The use of an antibody that binds to CD20 for the manufacture of a medicament for the treatment of rheumatoid arthritis in a mammal with an inadequate response to a TNFα inhibitor in which the mammal has an ACR50 response at week 24, an ACR70 response at week 24, or is not progressive the development of erosion in the 24th week and beyond. 2. Применение по п.1, в котором млекопитающим является человек.2. The use according to claim 1, in which the mammal is a human. 3. Применение по п.1, в котором антитело не конъюгировано с цитотоксическим агентом.3. The use according to claim 1, in which the antibody is not conjugated to a cytotoxic agent. 4. Применение по п.1, в котором антителом является ритуксимаб.4. The use according to claim 1, in which the antibody is rituximab. 5. Применение по п.1, в котором антитело является гумманизированным антителом 2Н7 v16, содержащим вариабельные домены, представленные SEQ ID Nos. 1 и 2.5. The use according to claim 1, in which the antibody is a humanized antibody 2H7 v16 containing the variable domains represented by SEQ ID Nos. 1 and 2. 6. Применение по п.1, при котором лекарственное средство применяется для лечения млекопитающего в способе, который, по существу, заключается во введении млекопитающему антагониста.6. The use according to claim 1, wherein the drug is used to treat a mammal in a method which essentially consists in administering an antagonist to the mammal. 7. Применение по п.1, при котором антитело вводится в качестве двух внутривенных доз по 1000 мг.7. The use according to claim 1, wherein the antibody is administered as two intravenous doses of 1000 mg. 8. Применение по п.1, при котором млекопитающее дополнительно получают сопутствующую терапию метотрексатом (МТХ).8. The use according to claim 1, in which the mammal additionally receive concomitant therapy with methotrexate (MTX). 9. Применение по п.8, при котором млекопитающее дополнительно лечат кортикостероидами.9. The use of claim 8, wherein the mammal is further treated with corticosteroids. 10. Применение по п.9, при котором кортикостероиды включают метилпреднизолон и преднизолон. 10. The use of claim 9, wherein the corticosteroids include methylprednisolone and prednisolone.
RU2008140661/15A 2006-04-09 2008-10-14 Using antibodies for treating autoimmune diseases in patient with inadequate response to tnf-alpha inhibitor RU2489166C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60/461,481 2003-04-09
US46148106P 2006-04-09 2006-04-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2005134394/14A Division RU2358762C9 (en) 2003-04-09 2004-04-06 Treatment of autoimmune diseases in patient suffering from inadequate response to tnf-alpha inhibitor

Publications (2)

Publication Number Publication Date
RU2008140661A true RU2008140661A (en) 2010-04-20
RU2489166C2 RU2489166C2 (en) 2013-08-10

Family

ID=46274896

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008140661/15A RU2489166C2 (en) 2006-04-09 2008-10-14 Using antibodies for treating autoimmune diseases in patient with inadequate response to tnf-alpha inhibitor

Country Status (1)

Country Link
RU (1) RU2489166C2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2639540C2 (en) * 2011-08-10 2017-12-21 Ланкенау Инститьют Фо Медикал Ресёрч Methods and compositions for autoimmune and inflammatory diseases treatment

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2724469C2 (en) 2018-10-31 2020-06-23 Закрытое Акционерное Общество "Биокад" Monoclonal antibody which specifically binds to cd20

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2203363A1 (en) * 1994-10-25 1996-05-02 Jean-Yves Marcel Paul Bonnefoy Binding agents to cd23
US5677189A (en) * 1995-06-29 1997-10-14 Oncomembrane, Inc. Method for quantifying sphingosine and for diagnosing platelet activation
JP2001058956A (en) * 1999-08-19 2001-03-06 Welfide Corp Autoimmune disease-preventing and treating agent

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2639540C2 (en) * 2011-08-10 2017-12-21 Ланкенау Инститьют Фо Медикал Ресёрч Methods and compositions for autoimmune and inflammatory diseases treatment

Also Published As

Publication number Publication date
RU2489166C2 (en) 2013-08-10

Similar Documents

Publication Publication Date Title
AU2018233032B2 (en) TEC family kinase inhibitor adjuvant therapy
US6623736B2 (en) Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
Tanaka et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus
RS52471B (en) Dosage regimen for the treatment of a traumatic brain injury with progesterone
US6471961B1 (en) Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
JP2004512262A5 (en)
JP2014114288A5 (en)
JP2002537356A (en) Tumor necrosis factor antagonist for treatment of neuropathy
RU2007132181A (en) ANTI-CANCER MEDICINE CONTAINING α, α, α-TRIFTORTIMIDINE AND A THIMIDINFOSPHORILYLASE INHIBITOR
CA2939464A1 (en) Use of anti-ccr5 antibodies in graft versus host disease
WO2018223923A1 (en) Use of pd-1 antibody combined with vegf ligand or vegf receptor inhibitor in preparing drug for treating tumor
PE20061075A1 (en) ANTI-VEGF ANTIBODIES AS ANTIANGIOGENIC AGENTS TO TREAT AUTOIMMUNE DISEASES IN PATIENTS IN WHOM PREVIOUS THERAPY FAILED
JP2020508317A5 (en)
JP2015172060A5 (en)
JP2018515493A5 (en)
JP2022160685A5 (en)
RU2014117510A (en) TREATMENT OF RHEUMATOID ARTHRITIS
CN114286828A (en) Dosing regimens and combination therapies for multispecific antibodies targeting B cell maturation antigens
Keystone B cells in rheumatoid arthritis: from hypothesis to the clinic
RU2016149316A (en) TREATMENT OF RHEUMATOID ARTHRITIS
RU2011117293A (en) COMPOSITION FOR TREATING A DISEASE
RU2008140661A (en) APPLICATION OF ANTIBODY FOR TREATMENT OF AUTOIMMUNE DISEASES IN A PATIENT WITH AN INadequate RESPONSE TO TNF-ALPH INHIBITOR
AR068531A1 (en) FIXED DOSE BY ONE INJECTION FOR OCRELIZUMAB (2H7). USE OF RITUXIMAB. PHARMACEUTICAL FORMULATION KIT
RU2394596C2 (en) Combined therapy by radioactively marked antibody anti-cd20 in treatment of b-cellular lymphoma
KR20180017145A (en) Treatment of pruritus